oruvestat (VX-01) / Vantage Biosciences - LARVOL DELTA

Vantage Biosciences Completes Enrollment in Phase 2 SeeClear Study of Oral Oruvestat in Non-Proliferative Diabetic Retinopathy (GlobeNewswire) - "With randomisation closed, all participants are now in the treatment and follow-up phase, with data readout expected in Q4 2027."

Enrollment closed • P2 data • Diabetic Retinopathy

Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy (GlobeNewswire) - "Vantage Biosciences...announced that the first patient has been successfully dosed in its Phase 2 clinical study evaluating VX-01, an oral therapy for the treatment of non-proliferative diabetic retinopathy (NPDR)."

Trial status • Diabetic Retinopathy